HK1044278B - β-卡林藥物產品 - Google Patents

β-卡林藥物產品

Info

Publication number
HK1044278B
HK1044278B HK02104540.5A HK02104540A HK1044278B HK 1044278 B HK1044278 B HK 1044278B HK 02104540 A HK02104540 A HK 02104540A HK 1044278 B HK1044278 B HK 1044278B
Authority
HK
Hong Kong
Prior art keywords
carboline
beta
drug products
drug
products
Prior art date
Application number
HK02104540.5A
Other languages
English (en)
Other versions
HK1044278A1 (en
Inventor
R Anderson Neil
J Hartauer Kerry
A Kral Martha
A Stephenson Gregory
Original Assignee
Icos Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22520112&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1044278(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Icos Corp filed Critical Icos Corp
Publication of HK1044278A1 publication Critical patent/HK1044278A1/xx
Publication of HK1044278B publication Critical patent/HK1044278B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Physical Or Chemical Processes And Apparatus (AREA)
HK02104540.5A 1999-08-03 2002-06-19 β-卡林藥物產品 HK1044278B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14704899P 1999-08-03 1999-08-03
PCT/US2000/020981 WO2001008688A2 (en) 1999-08-03 2000-08-01 Beta-carboline drug products

Publications (2)

Publication Number Publication Date
HK1044278A1 HK1044278A1 (en) 2002-10-18
HK1044278B true HK1044278B (zh) 2004-10-08

Family

ID=22520112

Family Applications (1)

Application Number Title Priority Date Filing Date
HK02104540.5A HK1044278B (zh) 1999-08-03 2002-06-19 β-卡林藥物產品

Country Status (33)

Country Link
EP (1) EP1200092B1 (zh)
JP (1) JP4456788B2 (zh)
KR (1) KR20020063842A (zh)
CN (2) CN1377270A (zh)
AR (1) AR033953A1 (zh)
AT (1) ATE264680T1 (zh)
AU (1) AU773666B2 (zh)
BR (1) BR0012901A (zh)
CA (1) CA2380087C (zh)
CO (1) CO5200849A1 (zh)
CZ (1) CZ300151B6 (zh)
DE (1) DE60010089T2 (zh)
DK (1) DK1200092T3 (zh)
DZ (1) DZ3180A1 (zh)
EA (1) EA004302B9 (zh)
ES (1) ES2220506T3 (zh)
HK (1) HK1044278B (zh)
HR (1) HRP20020091B1 (zh)
HU (1) HU229443B1 (zh)
IL (1) IL147642A0 (zh)
MX (1) MXPA02001197A (zh)
MY (1) MY125428A (zh)
NO (1) NO321602B1 (zh)
NZ (1) NZ516613A (zh)
PE (1) PE20010480A1 (zh)
PL (1) PL199469B1 (zh)
PT (1) PT1200092E (zh)
SK (1) SK286365B6 (zh)
SV (1) SV2002000137A (zh)
TW (1) TWI235658B (zh)
UA (1) UA71629C2 (zh)
WO (1) WO2001008688A2 (zh)
ZA (1) ZA200200825B (zh)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA004872B1 (ru) * 1999-08-03 2004-08-26 ЛИЛЛИ АЙКОС эЛ-эЛ-Си β-КАРБОЛИНОВЫЕ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ
EP2216329A1 (en) * 2004-10-28 2010-08-11 Dr. Reddy's Laboratories Ltd. Processes for the preparation of tadalafi
PL1808164T3 (pl) * 2006-01-05 2009-06-30 Teva Pharma Sposób z granulacją na mokro do wytwarzania kompozycji farmaceutycznych aripiprazolu
DE102007028869A1 (de) * 2007-06-22 2008-12-24 Ratiopharm Gmbh Verfahren zur Herstellung eines Arzneimittels enthaltend Tadalafil
MD4009C2 (ro) * 2008-07-15 2010-08-31 Институт Химии Академии Наук Молдовы Utilizarea 1-metil-4-(N-metilaminobutil-4)-β-carbolinei în calitate de remediu antituberculos
DE102009033396A1 (de) 2009-07-16 2011-01-20 Ratiopharm Gmbh Wässrige Lösung und gelatinierte Zusammensetzung umfassend einen Phosphodiesterase-5-Inhibitor sowie diesbezügliche Verfahren und Verwendung
DE102009035211A1 (de) 2009-07-29 2011-02-17 Ratiopharm Gmbh Copräzipitate umfassend einen Phosphodiesterase-5-Inhibitor (PDE-5-Inhibitor) und einen pharmazeutisch verträglichen Trägerstoff, ihre Herstellung und Verwendung
WO2012085927A2 (en) * 2010-12-02 2012-06-28 Mylan Laboratories, Limited Tadalafil compositions
WO2012095151A1 (en) 2010-12-23 2012-07-19 Zaklady Farmaceutyczne Polpharma Sa Solid pharmaceutical dosage forms comprising tadalafil and methods of preparation thereof
WO2012107541A1 (en) 2011-02-10 2012-08-16 Synthon Bv Pharmaceutical composition comprising tadalafil and a cyclodextrin
WO2012107092A1 (en) 2011-02-10 2012-08-16 Synthon Bv Pharmaceutical composition comprising tadalafil and a cyclodextrin
WO2012107090A1 (en) 2011-02-10 2012-08-16 Synthon Bv Granulated composition comprising tadalafil and a disintegrant
JP5930686B2 (ja) * 2011-12-07 2016-06-08 株式会社トクヤマ 溶解性および安定性の向上した難溶性医薬品原体及びその製造方法
KR102268695B1 (ko) 2012-03-15 2021-06-23 메르크 파텐트 게엠베하 전자 소자
WO2014003678A1 (en) * 2012-06-28 2014-01-03 Xspray Microparticles Ab Pharmaceutical compositions comprising ambrisentan and solid dispersion particles containing tadalafil
WO2014003677A1 (en) * 2012-06-28 2014-01-03 Xspray Microparticles Ab Pharmaceutical compositions comprising solid dispersion particles containing tadalafil
CN105310984A (zh) * 2014-06-10 2016-02-10 合肥贝霓医药科技有限公司 一种pde5抑制剂的超微粉体及其制备方法
CN105611918B (zh) * 2014-06-24 2018-08-14 株式会社宇信乐宝贴剂 含有他达拉非的口腔崩解型膜制剂及其制备方法
SI3466951T1 (sl) 2014-07-23 2022-05-31 Krka, D.D., Novo Mesto Proces za pripravo zaviralca CGMP-fosfodiesteraze in oralne farmacevtske formulacije, ki obsega koprecipitate tadalafila
JP2016106139A (ja) * 2016-03-07 2016-06-16 株式会社トクヤマ 溶解性および安定性の向上した難溶性医薬品原体及びその製造方法
AU2018397436A1 (en) * 2017-12-26 2020-08-13 Ftf Pharma Private Limited Liquid oral formulations for PDE V inhibitors
PT3510997T (pt) 2018-01-10 2020-10-07 Gap S A Cápsulas de gelatina mole compreendendo uma suspensão de tadalafil
CN110638770B (zh) * 2019-10-25 2022-04-05 株洲千金药业股份有限公司 他达拉非片剂的制备方法及以该方法制得的片剂
WO2023227185A1 (en) 2022-05-27 2023-11-30 Rontis Hellas S.A. Improved pharmaceutical composition containing tadalafil and nanomilling process for the preparation thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5618845A (en) * 1994-10-06 1997-04-08 Cephalon, Inc. Acetamide derivative having defined particle size
GB9511220D0 (en) * 1995-06-02 1995-07-26 Glaxo Group Ltd Solid dispersions

Also Published As

Publication number Publication date
EA200200119A1 (ru) 2002-06-27
CZ300151B6 (cs) 2009-02-25
CA2380087C (en) 2007-05-01
HK1044278A1 (en) 2002-10-18
NO321602B1 (no) 2006-06-12
NO20020531D0 (no) 2002-02-01
PT1200092E (pt) 2004-07-30
HU229443B1 (en) 2013-12-30
DZ3180A1 (fr) 2001-02-08
SK286365B6 (sk) 2008-08-05
DE60010089T2 (de) 2004-10-14
EP1200092B1 (en) 2004-04-21
AU773666B2 (en) 2004-06-03
AU6508400A (en) 2001-02-19
ZA200200825B (en) 2003-04-30
TWI235658B (en) 2005-07-11
AR033953A1 (es) 2004-01-21
WO2001008688A2 (en) 2001-02-08
MXPA02001197A (es) 2003-02-12
DK1200092T3 (da) 2004-08-16
CA2380087A1 (en) 2001-02-08
CZ2002387A3 (cs) 2002-10-16
CO5200849A1 (es) 2002-09-27
EA004302B1 (ru) 2004-02-26
JP4456788B2 (ja) 2010-04-28
KR20020063842A (ko) 2002-08-05
WO2001008688A3 (en) 2001-08-16
HRP20020091A2 (en) 2004-02-29
PL199469B1 (pl) 2008-09-30
HUP0202781A3 (en) 2003-10-28
PL353268A1 (en) 2003-11-03
HRP20020091B1 (en) 2006-02-28
CN101134019A (zh) 2008-03-05
JP2003505510A (ja) 2003-02-12
IL147642A0 (en) 2002-08-14
SV2002000137A (es) 2002-06-07
PE20010480A1 (es) 2001-05-26
EA004302B9 (ru) 2019-01-31
CN1377270A (zh) 2002-10-30
DE60010089D1 (de) 2004-05-27
ATE264680T1 (de) 2004-05-15
UA71629C2 (en) 2004-12-15
ES2220506T3 (es) 2004-12-16
SK1722002A3 (en) 2002-05-09
NZ516613A (en) 2003-08-29
BR0012901A (pt) 2002-04-16
EP1200092A2 (en) 2002-05-02
HUP0202781A2 (hu) 2002-12-28
MY125428A (en) 2006-07-31
NO20020531L (no) 2002-04-03

Similar Documents

Publication Publication Date Title
HK1044278A1 (en) Beta-carboline drug products
IL149224A0 (en) Hydrogen-driven drug dosage form
HUP0203585A3 (en) Pharmaceutical combinations
EG23858A (en) Drug combination
EG23937A (en) Novel pharmaceutical
GB9909041D0 (en) Novel pharmaceutical
IL146341A0 (en) Pharmaceutical complex
IL148543A0 (en) Pharmaceutical carrier formulation
EG23946A (en) Novel pharmaceutical
GB9909154D0 (en) Pharmaceutical formulation
GB9926251D0 (en) Pharmaceutical formulation
SI1200092T1 (en) Beta-carboline drug products
GB9917775D0 (en) Pharmaceutical formulation
GB9919840D0 (en) Pharmaceutical formulation
GB9917774D0 (en) Pharmaceutical formulation
GB9910636D0 (en) Pharmaceutical formulation
GB9921396D0 (en) Pharmaceutical formulation
GB9930700D0 (en) Pharmaceutical formulation
GB9917777D0 (en) Pharmaceutical formulation
GB9930878D0 (en) Pharmaceutical formulation
GB9927685D0 (en) Pharmaceutical formulation
GB9922187D0 (en) Pharmaceutical formulation
GB9917772D0 (en) Pharmaceutical formulation
GB9910633D0 (en) Pharmaceutical formulation
CA85983S (en) Pharmaceutical container

Legal Events

Date Code Title Description
PF Patent in force
PE Patent expired

Effective date: 20200731